While the identification of disease-driving gluten peptide sequences has transformed our current understanding of CeD, the full use of this insight in the food industry and for the clinical benefit of patients will require complete knowledge of gluten peptides that elicit CD4+ T cell activation in CeD. Here, CD4 is linked to cranioectodermal dysplasia.